dc.contributor.author | Shaw, Greg L. | |
dc.contributor.author | Wilson, Peter | |
dc.contributor.author | Cuzick, Jack | |
dc.contributor.author | Prowse, David M. | |
dc.contributor.author | Goldenberg, S. Larry | |
dc.contributor.author | Spry, Nigel A. | |
dc.contributor.author | Oliver, Tim | |
dc.date.accessioned | 2015-07-16T23:10:26Z | |
dc.date.available | 2015-07-16T23:10:26Z | |
dc.date.issued | 2007-05-01 | |
dc.identifier.citation | Shaw , G L , Wilson , P , Cuzick , J , Prowse , D M , Goldenberg , S L , Spry , N A & Oliver , T 2007 , ' International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate : A meta-analysis of 1446 patients ' , BJU International , vol. 99 , no. 5 , pp. 1056-1065 . https://doi.org/10.1111/j.1464-410X.2007.06770.x | |
dc.identifier.issn | 1464-4096 | |
dc.identifier.uri | http://hdl.handle.net/2299/16164 | |
dc.description.abstract | OBJECTIVE: To review pooled phase II data to identify features of different regimens of intermittent hormone therapy (IHT), developed to reduce the morbidity of treating metastatic prostate cancer, and which carries a theoretical advantage of delaying the onset of androgen-independent prostate cancer, (AIPC) that are associated with success, highlighting features which require exploration with prospective trials to establish the best strategies for using this treatment. METHODS: Individual data were collated on 1446 patients with adequate information, from 10 phase II studies with >50 cases, identified through Pubmed. RESULTS: Univariate and multivariate Cox proportional hazard models were developed to predict treatment success with a high degree of statistical success. The prostate-specific antigen (PSA) nadir, the PSA threshold to restart treatment, and medication type and duration, were important predictors of outcome. CONCLUSIONS: The duration of biochemical remission after a period of HT is a durable early indicator of how rapidly AIPC and death will occur, and will make a useful endpoint in future trials to investigate the best ways to use IHT based on the important treatment cycling variables described above. Patients spent a mean of 39% of the time off treatment. The initial PSA level and PSA nadir allow the identification of patients with prostate cancer in whom it might be possible to avoid radical therapy. | en |
dc.format.extent | 10 | |
dc.format.extent | 230224 | |
dc.language.iso | eng | |
dc.relation.ispartof | BJU International | |
dc.subject | Intermittent hormone treatment | |
dc.subject | Meta-analysis | |
dc.subject | Prostate cancer | |
dc.subject | Urology | |
dc.title | International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate : A meta-analysis of 1446 patients | en |
dc.contributor.institution | School of Life and Medical Sciences | |
dc.contributor.institution | Health & Human Sciences Research Institute | |
dc.contributor.institution | Department of Human and Environmental Sciences | |
dc.description.status | Peer reviewed | |
rioxxterms.versionofrecord | 10.1111/j.1464-410X.2007.06770.x | |
rioxxterms.type | Journal Article/Review | |
herts.preservation.rarelyaccessed | true | |